Adaptive MicroRNA Delivery Systems for Specialized Environments

Publication ID: 24-11857633_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive MicroRNA Delivery Systems for Specialized Environments,” Published Technical Disclosure No. 24-11857633_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857633_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,633.

Summary of the Inventive Concept

This inventive concept adapts phosphorothioate-conjugated miRNAs for specialized environments, such as disaster relief, high-security needs, and extreme weather conditions, enabling targeted delivery and improved efficacy in niche applications.

Background and Problem Solved

The original patent disclosed phosphorothioate-conjugated miRNAs for treating multiple myeloma and inhibiting IL-6 signaling. However, these miRNAs may not be suitable for extreme environments or specialized applications. This inventive concept addresses the limitations of the original patent by developing adaptable miRNA delivery systems for specific, high-need markets.

Detailed Description of the Inventive Concept

The inventive concept comprises a microRNA delivery platform adapted for extreme weather conditions, high-security data storage using phosphorothioate-conjugated miRNAs, a portable miRNA delivery unit for emergency response, a microRNA-based detection system for biodefense, and environmental remediation using phosphorothioate-conjugated miRNAs. These systems and methods leverage the original patent's miRNA conjugates to target specific applications, ensuring improved efficacy and stability in challenging environments.

Novelty and Inventive Step

The new claims introduce novel adaptations of the original patent's miRNA conjugates, including temperature and humidity resistance, secure encryption protocols, solar-powered portable units, and multi-pathogen detection capabilities. These specialized features and functionalities constitute the inventive step, distinguishing the new concept from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include miRNA delivery systems for space exploration, agricultural applications, or veterinary medicine. Variations could involve different types of miRNA conjugates, alternative encryption protocols, or modified detection systems.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including disaster relief, biodefense, environmental remediation, and high-security data storage. Target markets could include government agencies, emergency response organizations, and private companies operating in extreme environments.

CPC Classifications

SectionClassGroup
A A61 A61K47/549
A A61 A61K47/548
A A61 A61K48/00
C C12 C12N15/113
C C12 C12N2310/141
C C12 C12N2320/30

Field of Art

Molecular Biology and Pharmaceutical Biotechnology, focusing on microRNA delivery systems, nucleic acid conjugation, and targeted therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or biochemistry, experienced in nucleic acid manipulation, drug delivery technologies, and understanding of chemical conjugation techniques for therapeutic applications

Obviousness Rationale

A person having ordinary skill in the art would recognize that the source patent's phosphorothioate-conjugated miRNA technology provides a foundational platform for specialized adaptations. The PTD's variations represent predictable extensions of known miRNA delivery principles, applying the core conjugation technology to specific environmental and functional contexts. The technical modifications demonstrate routine engineering adaptations that would be apparent to a skilled practitioner seeking to optimize miRNA delivery in challenging conditions.

Obvious Combinations & Variations

Source Patent Element
Phosphorothioate-conjugated microRNA delivery system for cellular targeting
PTD Variation
Adaptation of miRNA delivery platform for extreme weather conditions with temperature and humidity resistance
Obviousness Reasoning
A PHOSITA would recognize that modifying conjugation chemistry to enhance environmental stability is a predictable solution using known materials science techniques, representing a straightforward design optimization
Source Patent Element
Non-cell penetrating ribonucleic acid conjugation method
PTD Variation
High-security data storage using encrypted miRNA delivery protocols
Obviousness Reasoning
Applying encryption techniques to existing molecular delivery systems represents a standard approach in biotechnology for enhancing information security, utilizing known cryptographic methods
Source Patent Element
MicroRNA targeting for cellular intervention
PTD Variation
Biodefense detection system for simultaneous multi-pathogen identification
Obviousness Reasoning
Extending miRNA detection capabilities to pathogen identification is a logical progression using multiplexing techniques common in diagnostic molecular biology
Source Patent Element
Phosphorothioate chemical conjugation of microRNAs
PTD Variation
Solar-powered portable miRNA delivery unit with GPS tracking
Obviousness Reasoning
Integrating power management and location tracking technologies with existing molecular delivery platforms represents a routine engineering solution with predictable implementation strategies
Source Patent Element
MicroRNA therapeutic targeting method
PTD Variation
Environmental remediation using targeted miRNA degradation of pollutants
Obviousness Reasoning
Repurposing molecular targeting strategies for environmental applications is a foreseeable extension of existing biotechnological intervention techniques
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857633 and the comprehensive disclosure herein, a person having ordinary skill in the art would find the claimed variations obvious and anticipated, as the technical modifications represent predictable adaptations of known phosphorothioate-conjugated microRNA delivery technologies, demonstrating no inventive step beyond the ordinary capabilities of skilled practitioners in molecular biotechnology.

Original Patent Information

Patent NumberUS 11,857,633
TitlePhosphorothioate-conjugated miRNAs and methods of using the same
Assignee(s)City of Hope